Abstract. Phenylketonuria (PKU) and hyperphenylalaninemia (HPA) are a group of genetic disorders predominantly caused by mutations in the phenylalanine hydroxylase (PAH) gene. To date, more than 950 variants have been identified in this gene, however the pathogenic mechanism of many variants remains unknown. In vitro and in silico functional study of PAH mutated enzymes enables to determinate whether the variant is pathogenic and to clarify the mechanism how the variant affects PAH enzyme function. In this study, we combined in silico prediction tools with in vitro prokaryotic and eukaryotic expression systems to characterize five PAH variants (p.F233I, p.R270I, p.F331S, p.S350Y and p.L358F) previously identified in Slovak and Czech patients with unknown effect. Variants p.F233I, p.R270I and p.S350Y PAH variants were classified as deleterious mutations since they showed no specific activity in functional assay and they did not respond to chaperone co-expression and the presence of BH4 precursor. Variants p.F331S and p.F358S exerted residual enzymatic activity in vitro, therefore both are classified as mild mutations.
Introduction
Phenylketonuria (PKU, OMIM 261600) and its milder forms, hyperphenylalaninemias (HPA), are a group of metabolic disorders inherited in an autosomal recessive manner. PKU and HPA are predominantly caused by the impairment of phenylalanine hydroxylase (PAH, EC 1.14.16.1). This enzyme catalyses conversion of the essential amino acid L-phenylalanine (L-Phe) to L-tyrosine (LTyr) in the presence of the cofactor 6(R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4), molecular oxygen and iron (Kobe et al. 1999) . In PKU patients, uncatabolised L-Phe and its toxic metabolic by-products accumulate in the blood, resulting in disturbed brain development, microcephaly, seizures, and other neurological symptoms (Williams et al. 2008) . Therefore, phenylalanine dietary intake in PKU patients must be strictly controlled (Guldberg et al. 1998; Blau et al. 2011 ).
PAH protein is expressed in the liver and kidneys (Wang et al. 1992; Lichter-Konecki et al. 1999) and it exists in cells in pH-dependent equilibrium between a homodimeric and homotetrameric form (Martinez et al. 1995) . Each monomer consists of three domains: the Nterminal regulatory domain (residues 1-142), the catalytic domain (residues 143-410) and the Cterminal oligomerization domain (411-452) (Kobe et al. 1999; Fusetti et al. 1998 ).
At present, there are more than 950 identified PAH variants which are distributed along the entire gene, of which approximately 60% are missense mutations (http://biopku.org/home/pah.asp).
Only a small percentage of PAH missense mutations have been functionally characterised. The impact of amino acid substitution on the protein function and stability can be predicted in silico by various software or it can be tested in vitro using prokaryotic and eukaryotic expression systems.
Previous studies show that more than 50 PAH missense mutations do not affect PAH gene transcription and in vitro expression of PAH mutants showed normal levels of mRNA compared to the wild type (wt), therefore mutation impact on PAH is mostly studied on the protein level (Desviat et al. 1995 , Dworniczak et al. 1991 , Waters et al. 1998 , Weinstein et al. 1993 . In E. coli, increased expression of mutant proteins leads to aggregate formation and subsequent protein degradation (Bjørgo et al. 1998) . Co-expression with GroEL and GroES bacterial chaperones can promote the proper folding of misfolded mutant proteins preventing them from degradation (Gámez et al. 2000) . Co-expression of mutated PAH enzymes in the presence with these chaperones, which are homologues of eukaryotic Hsp60 and Hsp10 (Feldman et al. 2000) , provides useful information whether the mutation is associated with decreased PAH protein stability caused by protein misfolding (Stojiljkovic et al. 2009 ).
Mutations with residual enzymatic activity are usually associated with mild PKU and non-PKU HPA, and these can respond to BH4, which has a chaperone-like effect on mild mutants and promotes correct folding and re-establishing of the oligomerisation equilibrium from dimer to tetramer (Blau et al. 2009; Cerreto et al. 2011) . Functional protein testing in eukaryotic expression systems in the presence of sepiapterin, which is a BH4 precursor, provides a useful tool for the assessment of whether the mutation is BH4 responsive. This information could be applied as a predictor in PKU treatment using BH4 supplementation.
We previously identified five PAH variants (p.F233I, p.R270I, p.F331S, p.S350Y, and p.L358F) in Slovak PKU patients with an unknown impact on the resultant protein (Polak et al. 2013 ). The variants p.F233I, p.R270I, and p.F331S, and p.S350Y were identified for the first time in the Slovak population while the p.L358F variant was identified in Czech PKU patients contemporaneously with our findings, and it was classified as a mild mutation by in silico analysis (Reblova et al. 2013 ). In the positions F233, R270, F331 and S350, other amino acid substitutions were also noted (Guldberg et al. 1998; Tyfield et al. 1997; Zhu et al. 2010; Kuzmin et al. 1995; Kleiman et al. 1993; Benit et al. 1994; Guldberg et al. 1996; Leuzzi et al. 2006 ), but only two of them, p.R270S and p.R270K, were functionally assayed in vitro (Bjørgo et al. 1998; Trunzo et al. 2016 ).
Recent studies underline the importance of PAH functional testing in terms of better understanding the genotype-phenotype correlations and the elucidation of BH4 responsiveness (Blau, 2016) . Thus, the aim of this work is to functionally and structurally characterise p.F233I, p.R270I, p.F331S, p.S350Y, and p.L358F PAH variants and contribute to a better understanding of PKU molecular basis.
Functional analysis of PAH mutated variants was performed in in vitro prokaryotic and eukaryotic expression systems. To extend the results, all variants were expressed in the presence of GroEL and GroES chaperones and sepiapterin, which has a chaperone-like effect on PAH protein.
Moreover, functional and structural analysis of all variants was performed using Molecular dynamics simulations and two consensus tools, Meta-SNP and PredictSNP.
Material and Methods

In silico analysis
The functional impact of each mutation on protein function was predicted using a Meta-SNP server (Capriotti et al. 2013 ) and consensus Classifier PredictSNP (Bendl et al. 2014) . These are webbased tools which combine the following nine methods: Panther, PhD-SNP, SIFT, SNAP, Meta-SNP, MAPP, Predict-SNP, PolyPhen-1, and PolyPhen-2.
The structural effect of four missense variants was also investigated using Molecular dynamics (MD) simulations. We used our previous 3D model of human PAH (Reblova et al. 2013) , where the catalytic domain (residues 143-410) and oligomerisation domain (residues 411-452) were built based on the X-ray structures of truncated forms of human PAH (pdb codes: 1PAH (Erlandsen et al. 1997 ) and 2PAH (Fusetti et al. 1998) ) while the N-terminal regulatory domain (residues 19-142) was built based on the homology modelling of rat PAH (pdb code: 1PHZ (Kobe et al. 1999) . Homology modelling was carried out using the Modeller 9.11 program (Sali and Blundell, 1993) . Based on the model of the human PAH monomer, we built the structure of the mutants p.F233I, p.R270I, p.F331S, and p.S350Y, which carried the mutations c.697T>A, c.809G>T, c.992T>C and c.1049C>A, using the Xleap module of AMBER 12 (Case et al. 2012) and the force field parm99SB (Hornak et al. 2006) . Using the Xleap module wild type (wt), mutant structures were neutralised by K + ions (Dang and Kollman, 1995) and solvated by an octahedral SPC/E water box extending 10 Å away from the solute. The equilibration and production phases were carried out using standard protocol (Reblova et al. 2015) . For wt and the mutant structures, we ran 100 nanosecond-long (ns) MD simulations. Trajectories were analysed using the Ptraj module of AMBER and visualised using VMD program (Humphrey et al. 1996) . We analysed the structural contacts of the studied residues (direct H-bonds with these criteria: the distance between the H-bond donor and acceptor below 3.2 Å and angle donor-hydrogen⋯acceptor >120°, salt bridges, and aromatic interactions between amino acids) and their buriedness corresponding to the relative accessible surface area (RSA)≤10%, which was calculated by measuring the accessible surface area of wt amino acid using the Stride program (Stride Web interface, Frishman ad Argos, 1995) and normalised by the maximum accessible surface area for the corresponding amino acid residue type (Chothia, 1976) .
Vectors and E. coli protein expression
The mutations c.697T>A, c.809G>T, c.992T>C, c.1049C>A, and c.1074A>T were introduced into the vector pMAL-MBP-c2 containing human wild type PAH cDNA by site-directed mutagenesis using a Phusion Site-Directed Mutagenesis Kit (Thermo Fisher Scientific) with specific primers (Supplementary Table 1 ). The pMAL-PAH constructs were transformed into E. coli Xl1 blue cells, which were used for plasmid propagation and PAH proteins expression, and selected by the appropriate antibiotics. Each clone for subsequent analyses was verified by sequence analysis. All mutant plasmids were also co-transformed with pGroELS plasmids coding GroEL and GroES bacterial chaperones. Each clone for subsequent analysis was verified by sequencing analysis.
Expression of mutated PAH proteins, fused with maltose binding protein (MBP), was performed as previously described (Martinez et al. 1995) . Briefly, expression of mutated enzymes was triggered by adding 100 mM IPTG and 0.2 mM ferrous ammonium sulphate into the cultivation medium.
After 18 hours of incubation, the bacterial cells were collected and sonicated in a buffer containing 200 mM NaCl, 20 mM Hepes and cOmplete Protease Inhibitor Cocktail (Roche), pH 7.0.
Purification of recombinant PAH fusion proteins
Wt PAH and each mutated form were purified by affinity chromatography using the ÄKTA avant 25 system (GE Healthcare Life Sciences), and MBPTrap™ HP 1 ml column (GE Healthcare Life Science) loaded with a column buffer containing 200 mM NaCl and 20 mM Hepes, pH 7.0. Elution of PAH-MBP was performed using 10mM maltose dissolved in the column buffer and proteins were subsequently purified by size-exclusion chromatography using a Superdex 200 HR 10/30 column (GE Healthcare Life Sciences) in the same column buffer. Protein concentration was then spectrophotometrically determined using Quick Start™ Bradford Protein Assay (Bio-Rad).
PAH functional assay
PAH functional assay was performed as previously described (Martinez et al. 1995) . It comprised of 1 µg of protein, pre-incubated for 4 minutes, with 10 mM L-Phenylalanine in the presence of 1 mg/ml catalase and 0.1 M NaHepes. Next, 100 μM ferrous ammonium sulphate was added and the mixture was incubated for a further minute. The reaction was initiated by adding 75 μM BH4 diluted in 5 mM DTT and terminated with 1% (v/v) acetic acid in ethanol after 1 or 5 minutes.
Enzymes were assayed in triplicates at 25°C in 50 μl reaction volumes.
Tyrosine and phenylalanine were separated by HPLC (Agilent 1100 series) in an analytical column Zorbax XDB-C18;150 x 4.6mm; 5 µm. The mobile phase was isocratic with the column temperature set at 30°C. Signals were detected by a fluorescence detector with an excitation wavelength of 210 nm and analysed by Chemstation software. Percentual specific activity was calculated from the molar concentration of forming L-tyrosine in the reaction of each PAH mutant in comparison to the wt PAH.
Eukaryotic expression system
pFLAG-PAH vectors were prepared by cloning PAH cDNA into the pFLAG-CMV vector through 
Western Blot Analysis
The transfected HepG2 cells were lysed in NP-40 lysis buffer containing 150 mM sodium chloride, 
Statistical analysis
Each protein was expressed in E.coli and purified in two independent experiments. Functional assay was performed using proteins from two independent affinity or size exclusion chromatography purifications in three replicates, each for proteins with or without co-transformed GroEL and GroES chaperones. Three independent Western blot analyses of PAH proteins expressed in HepG2 cells were performed. The results are presented as mean ± S.D. Statistical differences between multiple comparisons were performed using adjusted t-test.
Results
In silico analysis
The three p.R270I, p.F331S, and p.S350Y PAH variants were classified as deleterious mutations by all nine prediction methods, and the p.F233I and p.L358F variants were predicted as diseasecausing mutations by five of the programs (Table 1) .
We also investigated mutant proteins by using MD simulations. The behaviour of mutated residues was analysed based on 100 ns-long simulations and compared with wt simulation. Stability of the simulations was detected using Root Mean Square deviation (RMSd). This parameter reveals structural change from the initial starting structure, which was very small for wild-type and also for the mutated proteins on 100 ns time scale, particularly, averaged RMSd values of all systems were below 2 Å (Figure 1) . The changes we detected in the mutant simulations were rather local structural rearrangements, see below.
Residue F233 is positioned close to the protein surface (buriedness is 18%) in the hydrophobic pocket created by residues L212, I209 and L213. Simulation of the p.F233I mutant revealed that mutated isoleucine fits well into this position (Figure 2 ).
Residue R270 (buriedness is 5%) is positioned in a long turn, which is the entrance to the active site. The arginine forms a salt bridge with D282 and H-bond with P275 and both stabilise the long turn (Figure 2 and Figure 3 ). MD simulations of wt revealed both contacts to be stable. The substitution of large/charged arginine by small/hydrophobic isoleucine prevents such contacts (Figure 2 ). Conformational change of the long turn was observed in the p.R270I simulation (not seen in the wt simulation), which is probably due to the missing contacts (Figure 3 ). This kind of change may impact the functionality of the protein.
Residue F331 is positioned in turn in the active site (buriedness is 9%). It stacks onto W326
and it is adjacent to E330, which together with H285 coordinate Fe 3+ ion (Figure 2 ). MD simulation of wt revealed that the stacking between F331 and W326 is perfectly stable. The substitution F331
for serine abolishes the stacking interaction, additionally the presence of serine disrupts hydrophobicity of this area. Even though MD simulation of p.F331S mutant extended up to 200 ns did not show any large structural rearrangement in the active site, it is more likely that p.F331S mutation results in significant impairment of the protein structure/function, which would probably be visible on a longer (microsecond) time scale.
S350 is positioned at the beginning of the active site near protein surface (buriedness is 32%). In the X-ray structure, it creates H-bond to E353 via a water molecule (Figure 2 ). In the wt simulation, this contact changed to fluctuating direct H-bond between E353 and S350. Additionally, in the wt simulation, side chain hydroxyl of S350 formed fluctuating H-bond to the main chain oxygen of G346. These contacts stabilise the position of the S350 in the active site. In the mutant p.S350Y simulation, neither of these contacts were formed (Figure 2 ), nor any new interaction between S350 and the surrounding amino acid was created.
Prokaryotic PAH expression
Human wt PAH and its mutant forms were expressed in E.coli from the pMAL vector fused with MBP. After affinity and size-exclusion chromatography (Figure 4 ), all three forms (aggregates, tetramers, and dimers) of wt PAH were obtained, of which catalytically active tetrameric form accounted for 32% of the total affinity purified protein. (Table 2) .
Wt PAH and three mutant proteins were partially rescued in the presence of GroEL and GroES chaperones ( Table 2 ). The p.F233I mutant tetramer formation increased to almost 12% of the total purified protein, while the p.F331S and p.L358F mutant proteins had increased tetrameric forms to 46.04% and 63.72%, respectively. For the two mutant proteins, p.R270I and p.S350Y, the percentage ratio in the presence of chaperones remained unchanged.
PAH assay
Functional in vitro testing of PAH proteins was performed with tetrameric forms and affinity purified proteins used for mutants lacking tetramers. While p.F233I, p.R270I, and p.S350Y mutant proteins showed no detectable specific activity, the mutant p.L358F exhibited 52 ± 0.7% residual activity and p.F331S PAH specific activity was 99 ± 12,7% compared to wt PAH.
Specific activity was recovered by GroEL and GroES chaperones only in p.F233I mutant, whose residual activity increased to 0.6 ± 0.2% compared to wt PAH. While p.L358F and p.F331S
PAH showed no significant change in specific activity (57,7 ± 4,4% and 115 ± 17,9%), those of p.R270I and p.S350Y remained null. (Tab. 2).
Eukaryotic expression system
Human hepatal cells HepG2 were used for PAH expression to test the sepiapterin effect on the protein level. Proteins isolated from non-transfected HepG2 cells were controls for non-specific antibody binding. All mutant PAH levels differed significantly compared to wt PAH (all p-values < 0.00013). We observed a significant increase of the wt PAH protein level, up to 157,67 ± 8% after sepiapterin treatment (p=0.02), as well as in the case of the p.S350Y mutant protein where the protein level increased from 0,38 ± 0,3% up to 10,2 ± 2,5% (p=0.007) compared to wt PAH. While p.F233I and p.F331S exert a non-significant increase in the protein level, the protein level of p.L358F remained unchanged. The amount of mutant protein p.R270I was nearly undetectable and there was also no increase in the protein level after cultivation in the presence of sepiapterin ( Figure   5 ).
Discussion
The most frequent missense mutations were functionally and structurally characterised in several studies many years ago (Waters, 2003) . However, large-scale PKU studies continuously reveal novel variants with an unknown impact on PAH enzyme function (Polak et al. 2013; Reblova et al. 2013; Groselj et al. 2013; Trunzo et al. 2015) . Therefore, it is highly important to constantly update and extend these data which contribute to a better understanding of the complex PKU nature.
Moreover, data obtained in PAH functional analyses provide a beneficial tool for clinical praxis and BH4 cofactor treatment.
We functionally characterised five missense PAH variants p.F233I, p.R270I, p.F331S, and p.S350Y and p.L358F previously identified in the Slovak and Czech populations (Polak et al. 2013; Reblova et al. 2013) . All mutations are located in the catalytic domain and these were subjected to in silico analysis by Meta-SNP and PredictSNP web-based tools combining nine prediction programs. The three p.R270I, p. F331S, and p.S350Y mutations were identified as disease-causing mutations by all nine programs and the remaining p.F233I and p.L358F variants were classified as deleterious by five programs.
In silico prediction of p.R270I and p.S350Y PAH mutants was confirmed by in vitro testing, neither forming catalytically active tetramers nor exhibiting enzymatic activity. These same results were obtained after their co-expression with GroEL and GroES chaperones. These findings are consistent with Western blot results where cell protein levels of both PAH variants were close to zero, probably due to improper folding and consequent protein degradation (Gjetting et al. 2001; Kim et al. 2006; Pey et al. 2007; Waters 2003) . While cultivation with sepiapterin significantly affected only the p.S350Y PAH (p=0.007), where protein quantity increased to 10.2 ± 2,5% compared to untreated p.S350Y, the p.R270I protein level remained unchanged ( Figure 5 ). We assume that observed increase in p.S350Y level occurs through decreased protein degradation rate due to the increased steady-state level of PAH monomers caused by the BH4 chaperone-like effect.
As our MD simulation indicates, the substitution of hydrophobic isoleucine for the electrically charged arginine abolishes the salt bridge and hydrogen bond formation and subsequent interactions with D282 and P275 required for the stabilisation of loop structure, which is the entrance to the active site. Furthermore, substitution of the hydrophobic tyrosine for the polar serine in the p.S350Y mutant abolishes structural contact with E353, which exists in the X-ray wt protein and was observed in the wt simulation. Therefore, our results suggest that the PAH mutations p.R270I and p.S350Y are null PAH mutations with a severe impact on protein function. These data are consistent with genotype-phenotype correlations in our previous study (Polak et al. 2013 ). Mutation p.R270I was identified in two unrelated patients in a compound heterozygous state with mutations p.R408W, manifesting severe classical PKU (cPKU), and p.I306V associated with mild PKU (mPKU) phenotype, respectively. The mutation p.S350Y was found in a cPKU patient with one allele uncharacterised. It is interesting to note that this patient was also a carrier of the newly discovered PAH promoter variant (c.−30A>T) with an unknown impact (Polak et al. 2013 ).
According to the in silico prediction analysis, p.F233I should exhibit residual enzymatic activity. The residue F233 is positioned in a catalytic domain and completes the hydrophobic pocket on the protein surface (Flatmark and Stevens, 1999) . Our MD simulation indicates that it forms no direct structural contacts with neighbouring amino acids, and therefore phenylalanine substitution for isoleucine should not affect the protein folding. However, its predicted milder effect was not confirmed. Since p.F233I PAH does not form any tetramers, it did not exert any specific activity in in vitro testing. Although co-expression with chaperones enhanced the tetramer assembling, the specific activity was only 0.6 ± 0.2% compared to wt PAH (Table 2, Figure 4 ). This is consistent with the in vitro eukaryotic expression, where the protein levels were significantly lower than wt PAH (p=8E-7). Therefore, both in vitro results indicate that the mutation p.F233I has a severe impact on PAH protein function. Interestingly enough, clinical manifestation correlates with these in vitro findings as well, since this mutation was identified in compound heterozygosity with the well-characterised null mutation p.R408W, and the phenotype in this patient corresponded to severe PKU (Polak et al. 2013 ).
The PAH variants p.F331S and p.L358F were identified in one patient who suffered from hyperphenylalaninemia (Polak et al. 2013) . MD simulation indicates that the substitution of phenylalanine for serine in position 331 prevents the forming of the π-stacking interaction with W326, reported essential for stabilisation of the active site wall (Erlandsen and Stevens, 1999) , and consequent incorrect packaging. Moreover, F331 is adjacent to E330, which together with H285, coordinate ferric ion at the active site. Despite classification as a deleterious mutation by in silico analysis, our results suggest that p.F331S PAH displays in vitro enzymatic activity in PAH assay approximately equal to that of wt PAH (Table 2) ; both solely and together with co-expressed chaperones. This contradicts in vitro eukaryotic analysis where the p.F331S PAH protein levels were approximately 2.23 ± 1.6% compared to wt PAH. While the protein quantity increased to 5 ± 3.2% transfected HepG2 cells cultivated with sepiapterin, these low percentages may indicate defective oligomerisation, decreased stability or high rate of proteolytic degradation (Gjetting et al. 2001; Kim et al. 2006; Pey et al. 2007; Waters 2003; Waters et al. 2001) . Due to its mutationinduced PAH level reduction, p.F331S PAH variant could be classified as possibly pathogenic.
The p.L358F PAH variant predicted disease in silico causing mutation by five programs of all nine used, and it was previously characterised by MD simulation as a mutation with a milder protein effect (Reblova et al. 2013) , which is consistent with our in vitro assay results. MD simulation also indicates that leucine substitution for phenylalanine initiates new interaction where F358 stacks on the H201, which is in interaction with Thr200 through hydrogen bond. Although this new interaction does not disrupt the protein function, it reduces its activity (Reblova et al. 2013) . In vitro, this mutant exhibited approximately 50% residual activity compared to wt PAH with no significant change in activity when co-expressed with GroEL and GroES chaperones (Table   2 ). Moreover, the protein level expressed in HepG2 cells was the highest from all tested mutations with approximately 17.85 ± 6.4% compared to wt PAH, and it was BH4-nonresponsive since it showed no significant difference in protein quantity in the presence of sepiapterin. Such ambiguous results highlight the necessity of functional testing in mammalian cell cultures because these are more aligned with the natural environment (Waters, 2003) . Our combined results confirmed the in silico prediction of a milder p.L358F impact on the enzymatic function. Overall, since this variant exerted high residual activity of purified proteins in in vitro PAH assay and low expression level in the hepatoma cellular model, it can be considered a mild mutation. 
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